Illumina TruSight Tumor 170

Nov 07, 2016

Illumina has launched TruSight Tumor 170, a next-generation sequencing-based panel that targets SNVs, gene amplifications, gene fusions, and splice variants found in 170 cancer-related genes. The panel analyzes both DNA and RNA and requires 40 nanograms of input from formalin-fixed paraffin-embedded samples. The panel will begin shipping in the first quarter 2017 for research use only.

Breaking News

FDA Grants Marketing Authorization for Cue Health COVID-19 At-Home, Molecular Test
Germline Genetic Testing Rates in Cancer Patients Low in California, Georgia, Study Finds
BabySeq Project Unearths Actionable Genetic Variants Impacting Infants, Parents
Illumina Appeals FTC's Order to Divest Grail, Cites Government Overreach
AccuStem, University Hospitals Partner to Establish Clinical Utility of Cancer Recurrence Test

The Scan

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.

Active Lifestyle Linked to Type 2 Diabetes Prevention in People at High Genetic Risk

A study in the British Journal of Sports Medicine shows that an active lifestyle goes a long way in type 2 diabetes prevention.

Beneficial, Harmful Effects of Introgression Between Wild and Domesticated European Grapes

A paper in PNAS shows that European wild grapevines were an important resource for improving the flavor of cultivated wine grapes.

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.